



Universiteit
Leiden
The Netherlands

Pancreatic islet transplantation: studies on the technique and efficacy of islet isolation and transplantation

Burg, M.P.M. van der

Citation

Burg, M. P. M. van der. (1994, November 9). *Pancreatic islet transplantation: studies on the technique and efficacy of islet isolation and transplantation*. Retrieved from <https://hdl.handle.net/1887/3486604>

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3486604>

Note: To cite this publication please use the final published version (if applicable).

The ultimate goal of pancreatic islet transplantation is to reinstate normal blood glucose regulation in patients with insulin-dependent diabetes mellitus to improve the quality of life, and prevent, postpone or ameliorate the long-term complications of the disease and, thereby, promote longevity.

Diabetes mellitus

Diabetes mellitus is a disease characterised by chronic high levels of blood glucose (hyperglycemia) which affects 2-4% of the population of industrialised countries. Two primary types of diabetes are recognised. By far the most common form of diabetes is non-insulin-dependent diabetes mellitus (NIDDM). NIDDM usually begins in middle age, but can occur earlier or later, and patients are frequently overweight. These patients — who still have endogenous insulin production, though quantitatively or qualitatively insufficient to maintain normal glucose levels — may be treated by diet or oral drugs (sulfonylureas). Some patients are treated with insulin to improve glucose control, but insulin administration is not of vital importance. NIDDM is also called type-2 diabetes. Roughly 5-10% of all diabetic patients depend, however, entirely on insulin administration to prevent life-threatening ketoacidosis [1–3]. In these patients with so-called insulin-dependent-diabetes-mellitus (IDDM) — also called type-1 diabetes — the hyperglycemia is a consequence of the inability to produce insulin, due to the loss of the insulin producing β -cells within the pancreatic islets of Langerhans.

Both genetic and environmental factors — resulting in autoimmune destruction of the pancreatic β -cells — are involved in the development of IDDM. The conventional treatment with daily subcutaneous insulin injections is a life-saving intervention for patients devoid of β -cells, but this approach falls short of the glycemic control achieved in normal individuals by the continuous

moment-to-moment adjustment of insulin secretion by the β -cell in response to the small physiological changes of blood glucose levels — therefore, in general, chronic hyperglycemia cannot be prevented. IDDM usually starts in childhood, and 20–30 years later two-thirds of the patients end up with proliferative retinopathy, which impairs and threatens vision, and one-third of the patients end up with overt nephropathy, which leads to kidney failure requiring dialysis or a renal transplant — further, neuropathy, cardiovascular disease, and lower limb amputations are well-known complications [4–6]. The overall morbidity accounts for a one-third reduction of the life expectancy of the insulin-dependent diabetic patients [7–9].

Glucose control

It has become evident that the long-term complications of diabetes are to be considered as caused by derangement of glucose control instead of being manifestations of type-1 diabetes as such [10, 11]. The importance of tight glucose control [12] has recently conclusively been shown by the Diabetes Control and Complications Trial Research Group, which demonstrated that long-term tight control by intensive insulin treatment delays the onset and slows the progression of long-term diabetic complications [13]. Based on these data a strong case can be made for close to normal glucose regulation. The message for clinical practice is clear: near-normoglycemia must be the aim in all type-1 diabetic patients from diagnosis; however, new strategies are required for broad implementation of tight control in the diabetic population, while minimising the increased risk of hypoglycemic episodes concomitant with intensive treatment [12–15]. Now, considerable attention is focused on the education of patients for self-control [15, 16], and new techniques for the optimal delivery of insulin (and analogues) are currently examined [17] — such as, nasal insulin administration, polymeric capsules, and implantable pumps with glucose control by intermittent feedback from a glucose sensor ('artificial β -cell'). The refinement of these methods is anxiously awaited. As yet, technical problems hamper closed-loop insulin pumps, and current exogenous insulin delivery methods do not mimic the exquisite glucose control provided by the release of insulin and the counterregulatory hormone glucagon from native pancreatic islets [18].

In order to deliver insulin (and glucagon) at the right places, in right doses, and at right times, a rational choice would be transplantation of a normal pancreas or transplantation of only the islets in type-1 diabetic patients [19, 20]. At present pancreas transplantation is the only reliable method available to

realise long-term near-normoglycemia in diabetic patients [21, 22]. Pancreas transplantation, however, is a major operation [19, 23] and requires life-long immunosuppression — with its toxic side effects. This procedure will therefore probably never be applicable to diabetic children or young adults. Pancreas transplants are now generally restricted to a minority of type-1 diabetic patients who already have or simultaneously will have a kidney transplant for end-stage renal failure [24, 25]. Considering the usually advanced complications in these patients, no dramatic effects of the pancreas graft would be expected. Beneficial effects both in terms of morbidity, longevity, and quality of life have, nevertheless, been demonstrated. Morphological changes of the kidney graft are prevented or reversed, the nerve function improves, and the patient's quality of life considerably improves by the elimination of both the acute diabetic complications, the need for frequent insulin injections and glucose measurements, and other restrictions. [19, 21, 23, 26–31]

The transplantation of purified isolated islets potentially offers many additional advantages over pancreas transplantation:

- Because of the small mass of a purified adult human islet graft (~ 1 millilitre) and the small size of the individual islets (with diameters from 0.05–0.5 millimetre) islet implantation is simple and safe, consisting of little more than an injection of a few millilitres of an islet suspension.
- Islet 'banking' by cryopreservation or storage of islets in tissue culture [32, 33] allows (i) the simultaneous or repeated transplantation of the islets of multiple donors [32], (ii) sophisticated prospective matching [32, 34], (iii) in vitro manipulation prior to implantation to lower the immunogenicity [35–37], or (iv) in vitro encapsulation in semipermeable artificial membranes ('bioartificial pancreas') to eliminate the need for immunosuppressive therapy [38–40], and potentially xenotransplantation to obviate donor shortage [41].
- Islets can be implanted at immunoprivileged sites [42–46], and sites allowing portal physiological drainage of hormones [47–50]

Thus in contrast to transplantation of the 'big dirty island' (i.e. the whole pancreatic organ), transplantation of isolated islets could become available to patients before the onset of devastating complications and thereby prevent them. Recently, insulin independence following adult human islet allografting in insulin-dependent patients has demonstrated the feasibility of this approach [32, 51]. As yet, however, many problems still prevent the large-scale clinical application of this technique, although potential solutions are appearing in outlines [32]. Past accomplishments and a historical perspective of important

concepts and methods in the islet transplantation field are discussed below.

The pancreatic origin of diabetes mellitus

As far back as Egyptian times, 1500 BC, the syndrome of diabetes has been recognised, due to its remarkable symptoms of frequent and voluminous urination and unquenchable thirst [52]. For a long time the high production of urine was the major criterion of diagnosis. In 1685, Brunner was the first to observe these symptoms after partial pancreatectomy and duct ligation of the remnant pancreas in dogs — however, he did not think of the diagnosis 'diabetes' [53]. The sweet taste of urine was reported first in the Western world by Willis in 1674 [52]. Next, when chemical methods for glucose assessment became available in the early 1800s, sugar in the urine and later in blood became the criterion. In 1869, Paul Langerhans was the first to describe the islets — which were later named after him by Laguesse — as "groups of cells ... appearing as vivid yellow specks...with a diameter of 0.1 to 0.24 mm ... scattered throughout the pancreas" ; but Langerhans offered no explanation as to the nature of these 'groups of cells' [54]. The pancreatic origin of diabetes was first established in 1889 by Von Mering and Minkowski who observed glucose in the urine of dogs after pancreatectomy [55]. From 1890–1892 Hédon confirmed these experiments, and performed the first subcutaneous segmental pancreatic autograft (without interruption of the blood supply) in pancreatectomised dogs, and demonstrated that diabetes was prevented by some internal secretion prior to graft removal [56]. This was confirmed by Minkowski [57] in 1892, and by Thiroloix, who demonstrated by obliterating the pancreatic ducts with oil and lamp-black, that the fibrosed pancreas could likewise maintain normoglycemia in dogs [58]. Laguesse in 1893 not only proposed the name "islets of Langerhans" but also voiced for the first time the opinion that the islets were the seat of the internal secretion that served a regulatory function in carbohydrate metabolism [59]. Finally, in the early 1900s, after the link between diabetes and an abnormal histology of the human islets had been established by Opie and anatomical studies by Ssobolew had demonstrated that no diabetes develops after duct ligation induced atrophy of the acinar tissue as long as the islets remained intact [60], it was generally accepted that the islets produced a hormone — termed "insulin" by De Meyer in 1909 or "isletin" initially by Banting and Best [61, 62] — that plays an essential role in the regulation of glucose homeostasis.

Towards a cure of diabetes

Insulin administration

After initial unsuccessful attempts, from 1892 by Minkowski [57] and a host of other investigators, to treat diabetes by injection of pancreatic extracts, promising blood glucose lowering effects were finally obtained in animals and man by Zülzer in 1904, Paulesco in 1921, and Banting and Best in 1921 [55, 62, 63]. Toxic side-effects of these extracts, however, clouded the interpretation of data, and denied further clinical application, until Collip, Banting, Best, and McLeod discovered the purification of insulin which allowed the wide-spread successful treatment of diabetes from 1923.

Free grafts

The first attempt to treat insulin-dependent diabetes with pancreatic islet transplantation was performed by Williams and Harsant in 1893, who transplanted three pieces of a freshly slaughtered sheep's pancreas subcutaneously in a 15-year-old boy [64]. From this and similar experiments with free pancreatic grafts it became evident around the turn of the century that the survival of free grafts was threatened by necrosis due to the bulk of tissue and by autolysis due to the digestive enzymes [65–67]. Because the exocrine pancreas appeared unnecessary for treatment of diabetes, other approaches were adopted that aimed at transplantation of the islets without the potentially harmful exocrine pancreas. These new approaches comprised transplantation of either (i) islet-rich tissue such as the fetal or neonatal pancreas — and an allograft of cultured insulinoma tissue in one patient with transient success, by Gaillard at our institution (Lab. of Cell Biology and Histology) in 1944 [67] — , or (ii) islet-enriched, so-called, “modified” pancreatic grafts by duct obstruction of the pancreas, which results in atrophy of the exocrine tissue whilst largely preserving the islets [66, 67] — a method first proposed by Ssobolew in 1902 as “a means of isolating the islets ... and organotherapy for diabetes in a rational manner” [20]. An appropriately aged fetal or neonatal pancreas will provide islet-rich tissue that may continue to develop without the potential of autolysis. An initial intramuscular allotransplant attempt in man in 1928 was unsuccessful, but from the 1950s experiments in rodents have established the selective long-term survival of islets in these free grafts at several sites together with amelioration of the diabetic status of the recipient [66]. Over the past decade human fetal tissue has been shown to survive for up to a year in insulin-dependent patients and some graft functioning has been demonstrated; however, no substantiated cases of reversal of diabetes have been reported.

Progress in this field of transplantation has been slow, probably because only a few groups have committed themselves to this field of islet transplantation, or perhaps for reasons of lack of tissue supply and ethical problems [68, 69]. Attempts to transplant the “modified” pancreatic grafts were successful, provided they were either finely minced to the size of large islets [65], or vascularised [58, 66, 67].

Vascularised grafts

The first successful transplants of vascularised pancreatic grafts were made in dogs in the 1920s. Further refinement of pancreas transplantation techniques worked out in the 1950s and 1960s led to the first clinical attempts at vascularised pancreas allotransplantation from 1966 [67]. Most of these first attempts with pancreaticoduodenal grafts failed, mainly due to exocrine leakage that led to poor graft survival and high mortality, and this subdued the initial enthusiasm about clinical pancreas transplantation. Pancreas transplantation revived following the introduction in 1977 by Dubernard and coworkers [70] of the new method of obliterating the ductal system of a segmental pancreas with a solidifying polymer (neoprene), which induces a chronic pancreatic inflammation, leading to atrophy of the exocrine pancreas. This technique avoided most of the complications after ligation of the ducts such as possible leakage of the pancreatic enzymes through dissected lymph vessels, and also avoided the need for an anastomosis of the ductal system for the drainage of acinar enzymes to a hollow organ such as the small bowel — and thereby similar risks of leakage of the enzymes. Segmental duct-obiterated pancreas transplantation evolved to the first widely applied islet replacement technique in diabetic patients. The safety of this method is the most important advantage, but the long-term glucose control is subject of much discussion [71–80], and this modality of vascularised pancreatic islet transplantation has recently been superseded by an improved method of transplantation of the vascularised whole organ with bladder drainage of the exocrine secretion [25]. According to the International Pancreas Transplant Registry data close to 5000 pancreas transplants were performed since the revival of pancreas transplantation from 1977, and experienced centres currently report patient survival of over 90% and graft survival rates of 80–90% [25, 71].

Transplantation of collagenase-isolated islets

Basics. In mammals including man, the islets of Langerhans vary in size from roughly 0.05–0.5 millimetre in diameter, and are scattered throughout the

pancreas. The total number of islets in the human pancreas varies from about 0.5 to 2 million, and the total weight of these islets roughly amounts to 1 gramme — corresponding to approx. 1.5% of the adult human pancreas of ~70 gramme. An islet comprises from a few cells to several thousands cells of mainly four types, i.e.: glucagon secreting alpha cells, pancreatic polypeptide secreting PP cells, somatostatin secreting D-cells, and mostly (60–80% of all cells) the insulin secreting β -cells. The islets and the acinar structures in the pancreas of most mammals are surrounded and held together by a fine network of collagen-containing fibrous tissue and large inter-lobular septae, which can be degraded at 37°C using a collagenase-containing enzyme complex. After collagenase digestion of the pancreas the tissue is further dissociated mechanically e.g. by gentle shaking, or aspiration through needles to release the isolated islets. Large non-digested structures such as the capsule of the pancreas, ducts, and vessels, are retained by sieving. Because the density (specific gravity) of islets usually differs from the density of non-islet tissue, the islets may be separated by centrifugation in density solutions to obtain a pure islet suspension for transplantation by infusion in organs such as the liver and spleen.

Rodent islet isolation and first clinical attempts. Tedious microdissection techniques to isolate a small number of large islets for chemical and physiological experiments were reported by Bensley as early as 1911 [81], and Hellerström in 1964 [82], but Moskalewski's finding in 1965 at our institution (Lab. of Cell Biology and Histology) that the islets are released in large numbers from the chopped rodent pancreas after exposure to the digestive action of collagenase [83], opened the door to transplantation experiments. Two years later, Lacy and Kostianovsky [84] refined this method by (i) intraductal infusion of a saline solution resulting in distension of the rat pancreas prior to the chopping and collagenase digestion steps, and (ii) introduction of the concept of density gradient purification of islets — albeit using rather unsuccessful sucrose gradients. By intraductal distension, the mechanical disruption of tissue was improved, and thereby the exposure of tissue to the digestive collagenase action, which resulted in higher islet yields. Moskalewski demonstrated in 1969 the survival of collagenase-isolated islets from guinea pigs in culture and after transplantation in the pancreas and at other sites [49]. Next, in the early 1970s, a surge of interest developed in islet transplantation following reports of the amelioration of diabetes after transplantation of collagenase-isolated islets in the rat by Younoszai and coworkers in 1970 [85], and Ballinger and Lacy in 1972 [86] — who further introduced the now widely

used Ficoll density gradient technique for islet purification [81]. The several hundreds of islets needed to normalise the glycemia in diabetic rats for these and subsequent isogenic transplantation experiments were obtained from multiple donors (~3-6 animals). Besides separation of the islets by centrifugation in Ficoll density gradients, hand-picking of islets by pipette was used — and still is used [48, 87–89] — if high quality purification of islets is required, to exclude either contamination with non-islet tissue, or possible detrimental effects of density gradients. This protocol became the standard for rodent islet isolation during the next decade [81]. Subsequent application of this method to the pancreas of large animals and man was far less successful [81], due to the different more compact and fibrous nature of large mammalian pancreases. Since after collagenase dissociation of the large mammalian pancreas, islet-containing pancreatic microfragments rather than free isolated islets were obtained no efficient density purification was possible, but abandonment of the purification step nevertheless allowed successful intrasplenic autotransplantation of these pancreatic microfragments in pancreatectomised dogs from 1976 [90, 91]. In the late 1970s, several investigators transplanted non-purified human pancreatic microfragments into patients with diabetes [92]. As a result one IDDM patient was reported in 1979 in Zürich by Largiader to have stopped daily insulin therapy after receiving an intrasplenic allotransplant of pancreatic microfragments simultaneously with a kidney [93]. Generally, however the outcome of these first clinical islet transplantation attempts had been disappointing. The problems included apart from an insufficient islet mass, inadequate immunosuppressive therapy and complications of portal hypertension and disseminated intravascular coagulation from inadequate graft purity after allo- and autotransplantation [92, 94]. It was obvious that new methods tailored to the isolation of islets from large mammalian pancreases were essential.

New concepts for large mammal islet isolation. The major breakthrough for large animal islet isolation was the inclusion of collagenase in the intraductal perfusion solution — first introduced in dog experiments by Horaguchi and coworkers in 1981 [95]. By using the duct for collagenase delivery the dissociation of the large mammalian pancreas was improved to the point that first (i) a superior functional outcome after autotransplantation of pancreatic microfragments in dogs was obtained [96–99] and next (ii), after slight modifications, islets cleanly separated from acinar tissue could be obtained from the human pancreas by Gray and coworkers in 1984 [100]. Further refinement of several steps in large animal islet isolation procedures led to

more efficient isolation of islets cleanly cleaved from acinar tissue and thereby allowed efficient subsequent density gradient purification, which in the late 1980s led to successful transplantation of purified islets in large animals, and finally in man. These refinements comprised:

- new assessment methods that allowed direct comparison of the isolation outcome between centres [101–104]
- improved control over the temperature, pressure, and flow during intraductal collagenase delivery, either by injection or using a pump [92, 105, 106]
- the use of new collagenase preparations, and improved control over the conditions during digestion [106, 107]
- emphasis on a gentle approach to prevent fragmentation of islets [92, 106]
- substitution of solutions specifically designed for the hypothermic preservation of tissue, for the conventional physiological-salt type solutions during the cold phase of islet isolation — first introduced in 1989 by our group [108, 109]
- and, modifications by Ricordi and coworkers [110] of the continuous digestion-filtration method [81, 111] that allows the continuous collagenase digestion of large pancreatic fragments in a perfusion chamber equipped with a mesh screen and simultaneous release of isolated islets, which are saved from further digestion [92].

First in 1986, Alejandro and coworkers — who at that time used a rather complex method of collagenase perfusion via both the ducts and veins of the pancreas [112] — reported the isolation of a sufficient number of purified islet cells from one pancreas to allow autotransplantation in dogs, and soon other centres reported successful islet auto- and allotransplantation in dogs and monkeys [104, 113–116]. These experiments finally led in 1990 to the first well-documented report, from the St. Louis group [51], of insulin-independence in a type-1 diabetic recipient of a highly purified adult islet allograft.

Clinical islet transplantation. According to the International Islet Transplant Registry data [117] 214 adult islet allografts and one adult islet xenograft have been performed in humans between Dec 12, 1893, and Dec 31, 1993, at 30 different institutions (Table I.1). The total number of diabetic patients reported to be insulin independent (for at least 1 wk) after adult islet allotransplantation through Dec 31, 1993, was 25. Among these, two type-1 diabetic recipient of an islet allograft (after or simultaneous with a kidney allograft) have been insulin independent for ~2.5 years, and one pancreatectomised recipient of a

simultaneous islet and liver allograft has sustained euglycemia in the absence of exogenous insulin for more than 4 years now. Thus the feasibility of clinical islet transplantation has been proven.

Table 1.1

Islet Transplant Registry summary of adult islet allografts (and one xenograft*) through December 31, 1993

Institution	Year of transplant	No. of cases
Bristol*	1893	1
Newcastle-upon-Tyne	1916	2
Padova	1927	2
New York	1935	1
Leiden	1944	1
Petah Tikva	1968	1
Minneapolis	1974–1993	38
Zurich	1977–1988	8
Genoa	1978–1979	13
Hannover	1978	2
Detroit	1980–1985	7
Giessen	1980–1993	8
East-Berlin	1982–1987	8
St. Louis	1985–1993	25
Miami	1985–1993	13
Paris	1988–1991	7
Perugia	1989–1991	5
West-Berlin	1989	1
Edmonton	1989–1993	5
Milan	1989–1993	15
St. Louis/London, Ontario	1990–1992	4
Pittsburgh	1990–1993	30
Leicester	1991–1992	3
Oxford	1991–1993	3
Charlestown	1991	2
Los Angeles I	1992–1993	4
Madrid	1992–1993	3
Los Angeles II	1993	1
Verona	1993	1
Homburg/Saar	1993	1

In total 215 islet transplants were performed in 30 institutions.

Data from ITR Newsletter No. 5 Vol.4(No. 1), Hering et al. (eds) Giessen, 1994

Rationale of the studies in this thesis

Although it can be concluded, as noted above, that clinical islet transplantation is technically feasible and insulin-independence can be attained, as yet many problems still prevent the large-scale clinical application of this technique [21, 32, 94, 118–121] — but potential solutions are appearing in outlines.

Problematical issues include:

- the condition of donor tissue, control of the conditions during islet isolation, the variability of islet isolation outcome
- the quality control of yield, purity, integrity, viability, and sterility of islets
- the diagnosis and prevention of rejection of the grafts
- β -cell toxic side-effects of immunosuppressive drugs such as CsA
- the beneficial or detrimental effects of exposure of the islet tissue to unnatural environments after implantation in e.g. the liver or thymus
- the metabolic sequelae of isolating the islets from their natural environment
- the impact of the metabolic state of the recipient on graft function and survival.

The studies in this thesis addressed some of the aspects of: (i) the variability of islet isolation outcome, (ii) the conditions during islet isolation, and (iii) glucose regulation after islet transplantation — with special attention to the importance of insulinotropic gut hormones for isolated islet function.

These issues were studied in a dog model, because (i) previous metabolic data and pancreas transplantation related experience were obtained in this model (ii) the anatomy of the dog's pancreas is similar to the human pancreas regarding the technical isolation-related problems, and (iii) the logistics of large-scale islet isolation and transplantation can be developed in this large animal.

Donor-related and isolation-related variability

The variability of islet isolation outcome is considered a major obstacle for large scale clinical application. Both donor-related variables and conditions during islet isolation may determine the pretransplant quality and quantity of isolated islets. In order to study the efficacy of islet isolation, however, new methods and parameters for assessment are needed.

In previous studies morphometric assessment of the total volume of isolated islets was reported, but the efficacy of islet isolation was indirectly and not directly addressed, because the isolation outcome was not compared with the native volume and size of islets in the pancreas before isolation. Therefore a

new approach in islet isolation assessment was adopted: the morphometric assessment of the islets in the native pancreas, and after collagenase isolation of the islets, in order to quantitate (i) the efficacy of islet isolation, and (ii) the variance due to interindividual differences in donor characteristics such as age and body weight and differences in islet content of pancreases. This study is reported in Chapter 2.

Assessment of islet isolation outcome

Assessment of islet isolation outcome is generally restricted to the measurement of the volume of isolated islets, and rather subjective measures of the purity of the islet preparation after collagenase dissociation of the pancreas and subsequent islet purification in density gradients. In addition, convenient biochemical assessment of insulin and amylase yield has been reported in the past. These biochemical parameters are generally no longer reported, because many factors during organ procurement and subsequent islet isolation are considered to potentially affect the viability or quality and thereby the insulin and amylase content of pancreatic tissue. Actually, both the outcome per se and the assessment of the outcome of large mammalian, especially human, islet isolation is generally considered uncertain. Therefore, the islet and acinar components of the intact pancreas and isolated tissues were examined using both morphometric, biochemical, and histological parameters to, (i) study the outcome of collagenase isolation and density gradient purification with respect to the yield, integrity, and purity of islets; (ii) to determine the impact of the donor pancreas, and the isolation and purification steps on the variability of outcome; (iii) for comparison of both (morphometric and biochemical) assessment methods, and (iv) to study new parameters based on both these methods. This study is reported in Chapter 3.

Islet preservation in the University of Wisconsin solution

All previous islet isolation methods used conventional physiological salt-based solutions during islet isolation. After collagenase digestion of the pancreas the islets are generally, however, isolated in the cold (a non-physiological condition), and the tissue is thus in a situation analogous to the cold stored

Table 1.2

Comparison of the RPMI solution and the University of Wisconsin solution (UWS)

Components (mM)	RPMI	UWS
Cations		
Na ⁺	114	30
K ⁺	5	120
Mg ²⁺	0.4	5
Ca ²⁺	0.4	-
Anions		
Cl ⁻	110	-
lactobionate ⁻	-	100
HCO ₃ ⁻	5	-
SO ₄ ²⁻	0.4	5
PO ₄ ²⁻	6	25
Saccharides		
glucose	11	-
raffinose	-	30
Specific components	metabolites/Hepes	antioxidants/ Pentastarch

The mechanism of hypothermia-induced cell swelling is well-known. In the cold the ionic pumps in the cell membrane are suppressed, which leads to cell swelling — due to intracellular accumulation of sodium, chloride, and water — when the cell is bathed in a solution similar to the extracellular fluid (containing high sodium and chloride). The UWS has been designed to minimise cell swelling during cold storage of the pancreas — essentially by replacing chloride with lactobionate, which due to a larger molecular weight is relatively impermeable across the cell membrane. Likewise glucose is replaced by the larger raffinose molecule, and the impermeant Pentastarch also counteracts cell swelling.

organ. Therefore, it seemed more logical to use the University of Wisconsin solution (UWS) — a solution originally designed specifically for preservation of the pancreas during cold storage prior to pancreas transplantation [122–124] — for islet isolation, and the effect of substitution of the UWS for the conventional RPMI tissue culture solution was explored. Next, after finding that islet isolation in the UWS greatly improves the outcome of density gradient purification [108–109]: the hypothesis was formulated and examined that (i) the UWS prevents cell swelling at low temperature during islet isolation and purification, and (ii) thus, preserves the normal density difference between islet and non-islet tissue, and, thereby, allows complete purification in density gradients, and further (iii) may improve the viability of islets. This study is presented in Chapter 4. The components of the UWS and the RPMI tissue culture solution that are important for cell volume regulation are illuminated, in Table I.2.

Metabolic control by isolated islets

The thesis that diabetic complications are halted or prevented by continuous precise glycemic control is central to the concept of islet transplantation. Therefore, it is essential to establish whether islet transplantation can produce adequate long-term metabolic control. The main focus in the islet transplantation field has been on technical and immunological issues, and metabolic control generally received scant attention. The clinical work is still anecdotal, and experimental studies in preclinical models are generally confined to intravenous glucose tolerance testing — thus, detailed studies are needed, that address the insulin secreting capacity, insulin action, and particularly the performance of transplanted islets under normal physiological conditions [125].

The normal native islet function is a result of the anatomical and physiological neural, hormonal, and other interrelations of the gastro-entero-pancreatic axis, at several levels.

- At the bottom level of the individual islet, the islet architecture determines (i) the path of the intra-islet blood flow, (ii) intercellular communication via gap-junctions, and (iii) paracrine effects of the islet hormones, insulin, glucagon, pancreatic polypeptide, and somatostatin [18, 126, 127].
- At the next level within the pancreas: the islets are interrelated via an intramural network of the intrinsic nerves, which co-ordinates the pulsatile delivery of islet hormones [128].
- At the top level of the gastro-entero-pancreatic axis (and interrelated

systems, e.g. the central nervous system) the islets communicate via nutrients and both neural and hormonal interrelations with other organs and the exocrine pancreatic component [129–132].

Pancreatic islet isolation and transplantation leads to destruction or disturbance of at least some of these interrelations. The issue of the extent of isolation of islets after pancreatic islet transplantation and the repercussions for glucose regulation are addressed in the next chapters.

Metabolic sequelae after duct obliteration induced 'isolation' of the islet cells. Our previous studies have demonstrated that duct obliteration induces complete atrophy of the exocrine tissue, reduces the islet mass to roughly 50% of the normal endocrine mass, and disrupts the normal native islet architecture. These histological changes are accompanied with a deterioration of glucose tolerance and insulin secretion during intravenous glucose stimulation tests within the first posttransplant month [72–76]. A study of the concurrent interruption of the enteropancreatic axis is reported in Chapter 5. The functional data in this study demonstrated that duct obliteration not only eliminates the exocrine pancreas but also results in the in vivo intrinsic denervation of the islets. Thus the duct obliterated pancreas graft eventually ends as a graft of 'isolated' islet cells. From the metabolic data in this study it was suggested for the first time that following intrinsic denervation after pancreatic islet transplantation non-pulsatile delivery of the islet hormones may lead to postprandial hyperglycemia, and a hyperglycemia-enhanced enteroinsular axis may contribute to postprandial normo- or hyperinsulinemia after transplantation.

Physiological, insulinotropic effects of gut hormones during in vitro perfusion of isolated islets. The duct obliteration study suggested the importance of hyperglycemia-enhanced insulinotropic effects of gut hormones after pancreatic islet transplantation. However, direct effects of physiological ('circulating') levels of potential insulinotropic gut hormones such as cholecystokinin (CCK), gastric inhibitory polypeptide (GIP) and the recently discovered incretin glucagon-like peptide (GLP-1) on isolated islets had not been reported. Therefore, the insulinotropic effects of these hormones were tested during in vitro perfusion of collagenase isolated islets at glucose levels as observed postprandially after pancreas and isolated-islet transplantation. This study is reported in Chapter 6.

Metabolic control after autotransplantation of isolated islets. Two consecutive series

of detailed metabolic studies after autotransplantation of collagenase-isolated islets in pancreatectomised dogs were performed. The first series of metabolic studies compared preoperative and postoperative data in dogs (that were their own controls) with emphasis after islet autografting on the natural history of the grafts, the comparison of intravenous versus oral stimulation tests, functional assessment of possible re-innervation, the metabolic contribution of the four major islet hormones (insulin, glucagon, pancreatic polypeptide, and somatostatin), the graft's insulin secreting capacity, and the predictive value of early posttransplant metabolic parameters for graft's life expectancy. This study is reported in Chapter 7. The second series of metabolic studies was performed in dogs with established islet autografts at 6 mo posttransplant (*vs* normal controls) with emphasis on the contribution of the insulin secreting capacity and intrinsic denervation of the islets to insulin resistance after grafting, the correlation of the insulin secreting capacity and action with postprandial performance, and the *in vivo* incretin effect during infusion of the major gut hormone GLP-1 at hyperglycemia after islet transplantation. This study is reported in Chapter 8.

References

1. Åkerblom HK, Reunanen A: The epidemiology of insulin-dependent diabetes mellitus (IDDM) in Finland and in Northern Europe. *Diabetes Care* 8 (Suppl 1): 10–16, 1985
2. Vaandrager GJ, Bruining GJ, Veenhof FJ, Drayer NM: incidence of childhood diabetes in The Netherlands: a decrease from north to south over North-Western Europe? *Diabetologia* 27: 203–206, 1984
3. Moy CS. Diabetes, 1991 Vital Statistics. American Diabetes Association, 1991
4. Andersen AR, Sandahl Christansen J, Andersen JK, Kreiner S, Deckert T: Diabetic nephropathy in type I (insulin-dependent) diabetes: an epidemiological study. *Diabetologia* 25: 496–501, 1983
5. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH: Prevalence of complications in IDDM by sex and duration: Pittsburgh epidemiology of diabetes complications study II. *Diabetes* 39: 1116–1124, 1990
6. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J: Declining incidence of nephropathy in insulin-dependent diabetes mellitus. *N Engl J Med* 330: 15–18, 1994
7. Diabetes epidemiology research international mortality study group: International evaluation of cause-specific mortality and IDDM. *Diabetes Care* 14: 55–60, 1991
8. Diabetes epidemiology research international mortality study group: Major cross-country differences in risk of dying for people with IDDM. *Diabetes Care* 14: 49–54, 1991
9. Deckert T, Poulsen JE, Larsen M: Prognosis of diabetics with diabetes onset before the age of thirtyone. I. Survival, causes of death, and complications. *Diabetologia* 14: 363, 1978
10. Ingelfinger FJ: Debates on diabetes. *N Engl J Med* 296: 1228–1230, 1977
11. The Kroc collaborative study group: Blood glucose control and the evolution of diabetic retinopathy and albuminuria. *N Engl J Med* 311: 365–372, 1984
12. American Diabetes Association: Implications of the Diabetes Control and Complications

- Trial. *Diabetes* 42: 1555–1558, 1993
13. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 329: 977–986, 1993
 14. Boulton AJM: DCCT: Implications for diabetes care in the UK. *Diabetic Medicine* 10: 687, 1993
 15. Santiago JV: Lessons from the Diabetes Control and Complications Trial. *Diabetes* 42: 1549–1554, 1993
 16. European IDDM policy group 1993: Consensus guidelines for the management of insulin-dependent (Type 1) diabetes. *Diabetic Medicine* 10: 990–1005, 1993
 17. 13th Workshop of the AIDSPIT Study Group, Igls, Austria, January 23–25 1994. *Horm metab Res* 26, 1994
 18. Carroll PB: Anatomy and physiology of islets of Langerhans. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 7–18
 19. Lefèbvre PJ: Pancreatic transplantation: why, when and who?. *Diabetologia* 35: 494–497, 1992
 20. Ssobolew LW: Zur normalen und pathologischen Morphologie der inneren Secretion der Bauchspeicheldrüse. *Virchows Arch path Anat* 168: 122, 1902
 21. Robertson RP: Pancreatic and islet transplantation for diabetes—Cures or curiosities? *N Engl J Med* 327: 1861–1868, 1992
 22. Katz H, Homan M, Velosa J, Robertson P, Rizza R: Effects of pancreas transplantation on postprandial glucose metabolism. *N Engl J Med* 325: 1278–1283, 1991
 23. Nathan DM, Fogel H, Norman D, Russell PS, Tolkoﬀ-Rubin N, Delmonico FL, Auchincloss H Jr., Camuso J, Cosimi AB: Long-term metabolic and quality of life results with pancreatic/renal transplantation in insulin-dependent diabetes mellitus. *Transplantation* 52: 85–91, 1991
 24. American Diabetes Association: Technical review on pancreas transplantation for patients with diabetes mellitus. *Diabetes Care* 16 (Suppl 2): 49–53, 1993
 25. Sutherland D, Gruessner A, Moudry-Munns K: International Pancreas Transplant Registry report. *Transplant Proc* 26: 407–411, 1994
 26. Navarro X, Kennedy WR, Loewenson RB, Sutherland DER: Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes mellitus. *Diabetes* 39: 802–806, 1990
 27. Bilous RW, Mauer SM, Sutherland DER, Najarian JS, Goetz FC, Steﬀes MW: The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. *N Engl J Med* 321: 80–85, 1989
 28. Bohman S-O, Tydén G, Wilczek H, Lundgren G, Jaremko G, Gunnarsson R, Ostman J, Groth CG: Prevention of kidney graft diabetic nephropathy by pancreas transplantation in man. *Diabetes* 34: 306–308, 1985
 29. Solders G, Wilczek H, Gunnarsson R, Tydén G, Persson A, Groth C-G: Effect of combined pancreatic and renal transplantation on diabetic neuropathy: a two-year follow-up study. *Lancet* 2: 1232–1235, 1987
 30. Ramsay RC, Goetz FC, Sutherland DER, Mauer SM, Robison LL, Cantrill HL, Knobloch WH, Najarian JS: Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes. *N Engl J Med* 318: 208–214, 1988
 31. Kennedy WR, Navarro X, Goetz FC, Sutherland DER, Najarian JS: Effects of pancreatic transplantation on diabetic neuropathy. *N Engl J Med* 322: 1031–1037, 1990
 32. Hering BJ, Browatzki CC, Schultz A, Bretzel RG, Federlin KF: Clinical islet

- transplantation—registry report, accomplishments in the past and future research needs. *Cell Transplant* 2: 269–282, 1993
33. Rajotte RV, Warnock GL, Kneteman NM: Methods of islet cryopreservation. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 400–409
 34. Bretzel RG, Flesch BK, Brennenstuhl G, Greiner I, Hering BJ, Woehrle M, Federlin K: Rat pancreatic islet pretreatment with anti-MHC class II monoclonal antibodies and culture: in vitro MLIC test response does not predict islet allograft survival. *Acta Diabetol* 30: 49–56, 1993
 35. Kenyon NS, Strasser S, Alejandro R: Ultraviolet light immunomodulation of canine islets for prolongation of allograft survival. *Diabetes* 39: 305–311, 1990
 36. Pipeleers DG, Pipeleers-Marichal M, Vanbrabant B, Duys S: Transplantation of purified islet cells in diabetic rats: II. immunogenicity of allografted islet β -cells. *Diabetes* 40: 920–930, 1991
 37. Bretzel RG, Flesch BK, Hering BJ, Brendel M, Klitscher D, Brandhorst H, Schelz J, Münch KP, Federlin K: Impact of culture and cryopreservation on MHC class II antigen expression in canine and porcine islets. In *Methods in islet transplantation research: international workshop, Bad Neuheim, June 1989*. Federlin K, Bretzel RG, Hering BJ, Hetzel WD, Hoffmann AR, Pfeiffer EF, Reaven GM, Eds. New York, Thieme Medical Publ., 1990, p. 128–132
 38. Reach G: Bioartificial pancreas. *Diabetic medicine* 10: 105–109, 1993
 39. Lanza RP, Borland KM, Lodge P, Carretta M, Sullivan SJ, Muller TE, Solomon BA, Maki T, Monaco AP, Chick WL: Treatment of severely diabetic pancreatectomized dogs using a diffusion-based hybrid pancreas. *Diabetes* 41: 886–889, 1992
 40. Calafiore: Transplantation of microencapsulated islets in nonimmunosuppressed diabetic recipients. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 439–447
 41. Hering BJ: Islet xenotransplantation. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 313–335
 42. Woehrle M, Markman JF, Beyer K, Naji A, Bretzel RG, Federlin K: The influence of the implantation site (kidney capsule vs. portal vein) on islet survival. In *Methods in islet transplantation research: international workshop, Bad Neuheim, June 1989*. Federlin K, Bretzel RG, Hering BJ, Hetzel WD, Hoffmann AR, Pfeiffer EF, Reaven GM, Eds. New York, Thieme Medical Publ., 1990, p. 163–165
 43. Posselt AM, Barker CF, Tomaszewski JE, Markmann JF, Choti MA, Naji A: Induction of donor-specific unresponsiveness by intrathymic islet transplantation. *Science* 249: 1293–1295, 1990
 44. Brayman KL, Nakai I, Field MJ, Lloveras JJ, Jessurun J, Najarian JS, Sutherland DER: Evaluation of intrathymic islet transplantation in the prediabetic period. *Surgery* 112: 319–326, 1992
 45. Tze WJ, Tai J: Allotransplantation of dispersed single pancreatic endocrine cells in diabetic rats. *Diabetes* 37: 383–392, 1988
 46. Chul Lee H, Jin Ahn K, Kil Lim S, Rae Kim K, Soo Ahn Y, Eun Lee K, Bum Huh K: Allotransplantation of rat islets into the cisterna magna of streptozotocin-induced diabetic rats. *Transplantation* 53: 513–516, 1992
 47. Rilo HLR, Fontes PA, Nussler AK, Demetris AJ, Carrall PB, Ildstad ST, Tzakis AG, Starzl TE, Ricordi C: Intrapancreatic islet transplantation as a potential solution to chronic failure of intraportal islet grafts. *Transplant Proc* 25: 988, 1993
 48. Van Suylichem PTR, Strubbe JH, Houwing H, Wolters GHJ, Van Schilfgaarde R: Insulin secretion by rat islet isografts of a defined endocrine volume after transplantation to three

- different sites. *Diabetologia* 35: 917–923, 1992
49. Moskalewski S: Studies on the culture and transplantation of isolated islets of Langerhans of the guinea pig. *Kon Ned Ac Wetenschap* 72: 157–171, 1969
 50. Lim SML, Li SQ, Poh LH, Lim NK, Seah ML, Heng KK: The rectum as a novel site for islet cell transplantation. *Transplantation* 57: 294–296, 1994
 51. Scharp DW, Lacy PE, Santiago JV, McCullough CS, Weide LG, Falqui L, Marchetti P, Gingerich RL, Jaffe AS, Cryer PE, Anderson CB, Flye MW: Insulin independence after islet transplantation into type I diabetic patient. *Diabetes* 39: 515–518, 1990
 52. Von Engelhardt D: Outlines of historical development. In *Diabetes its medical and cultural history*. Von Engelhardt D, Ed. Berlin Heidelberg, Springer-Verlag, 1989, p. 3–10
 53. Zimmermann OC: The first description of the symptoms of experimental pancreatic diabetes by the Swiss Johann Conrad Brunner (1653–1727). In *Diabetes its medical and cultural history*. Von Engelhardt D, Ed. Berlin Heidelberg, Springer-Verlag, 1989, p. 209–228
 54. Langerhans P: Beiträge zur Mikroskopischen Anatomie der Bauchspeicheldrüse. Thesis, Friedrich-Wilhelms-Universität, Berlin, 1869
 55. Luft R: Oskar Minkowski: Discovery of the pancreatic origin of diabetes, 1889. *Diabetologia* 32: 399–401, 1989
 56. Hédon E: Greffe sous-cutanée du pancréas. *Arch Physiol Norm Pathol* 5: 617–628, 1892
 57. Minkowski O: Weitere Mittheilungen über den Diabetes Mellitus nach Exstirpation des Pankreas. *Berl Klin Wochenschrift* 29: 90–94, 1892
 58. Thiroloix J: Note sur la physiologie du pancréas: de la dissociation expérimentale des sécrétions externe et interne de la glande—rôle dans le diabète. *Arch Physiol Norm Pathol* 4: 716–720, 1892
 59. Laguesse GE: Sur la formation des îlots de Langerhans dans le pancréas. *Compt Rend Soc Biol Paris* 45: 819–820, 1893
 60. Gepts W: Islet changes in human diabetes. In *The islets of Langerhans*. Cooperstein SJ, Watkins D, Eds. New York, Academic Press, 1981, p. 321–356
 61. Minkowski O: Historical development of the theory of pancreatic diabetes. *Diabetes* 38: 1–6, 1989
 62. Schadewaldt H: The history of diabetes mellitus. In *Diabetes its medical and cultural history*. Von Engelhardt D, Ed. Berlin Heidelberg, Springer-Verlag, 1989, p. 43–100
 63. Pratt JH: On the history of the discovery of insulin. In *Diabetes its medical and cultural history*. Von Engelhardt D, Ed. Berlin Heidelberg, Springer-Verlag, 1989, p. 411–419
 64. Williams PW: Notes on diabetes treated with extract and by grafts of sheep's pancreas. *Br Med J* 2: 1303–1304, 1894
 65. Hultquist GT, Thorell J: A method for isolating islets of Langerhans by transplantation. *Acta Soc Med Upsal* 69: 291–303, 1964
 66. Downing: Historical review of pancreatic islet transplantation. *World J Surg* 8: 137–142, 1984
 67. Lillehei RC, Idezuki Y: Current status of pancreatic transplantation. In *Organ transplantation today*. Mitchison NA, Greep JM, Hattanga Verschure JCM, Eds. Amsterdam, Excerpta Medica, 1969, p. 175–209
 68. Gray DWR, Morris PJ: Developments in isolated pancreatic islet transplantation. *Transplantation* 43: 321–331, 1987
 69. Stegall MD, Sutherland DER, Hardy MA: Registry report on clinical experience with islet transplantation. In *Transplantation of the endocrine pancreas in diabetes mellitus*. Van Schilfgaarde R, Hardy MA, Eds. Amsterdam, Elsevier Science, 1988, p. 224–233

70. Dubernard JM, Traeger J, Neyra P, Touraine JL, Tranchant D, Blanc-Brunat N: A new method of preparation of segmental grafts for transplantation: trials in dogs and man. *Surgery* 84: 633–639, 1978
71. Sutherland DER, Gores PF, Farney AC, Wahoff DC, Matas AJ, Dunn DL, Gruessner RWG, Najarian JS: Evolution of kidney, pancreas, and islet transplantation for patients with diabetes at the university of Minnesota. *Am J Surg* 166: 456–491, 1993
72. Gooszen HG. Canine segmental pancreatic autotransplantation. Analysis of the effects of ductobliteration. Thesis, Leiden, 1984
73. Gooszen HG, Van Schilfgaarde R, Frölich M, Van der Burg MPM: The effect of ductobliteration and of autotransplantation on the endocrine function of canine pancreatic segments. *Diabetes* 34: 1008–1013, 1985
74. Gooszen HG, Van Schilfgaarde R, Van der Burg MPM, Van Lawick van Pabst WP, Frölich M, Bosman FT: Quantitative assessment of long-term changes in insulin secretion after canine duct-obliterated pancreas transplantation. *Transplantation* 46: 793–799, 1988
75. Gooszen HG, Van der Burg MPM, Guicherit OR, Jansen JBMJ, Frölich M, Van Schilfgaarde R, Lamers CBHW: Crossover study on the effects of duct obliteration, celiac denervation, and autotransplantation on glucose- and meal-stimulated insulin, glucagon, and pancreatic polypeptide levels. *Diabetes* 38 (Suppl 1): 114–116, 1989
76. Gooszen HG, Bosman FT, Van Schilfgaarde R: The effect of duct obliteration on the histology and endocrine function of the canine pancreas. *Transplantation* 38: 13–17, 1984
77. Pozza G, Secchi A: Evaluation of endocrine function in pancreas transplant recipients. In *Transplantation of the endocrine pancreas in diabetes mellitus*. Van Schilfgaarde R, Hardy MA, Eds. Amsterdam, Elsevier Science, 1988, p. 337–340
78. Martin X, Dubernard JM, Sanseverino R, Melandri M, Faure JL, Camozzi L, LeFrancois N, La Rocca E, Gelet A: Segmental duct-obstructed pancreas grafts versus pancreaticoduodenal grafts with enteric diversion. *Diabetes* 38 (Suppl 1): 16–17, 1989
79. Liu T, Sutherland DER, Heil J, Dunning M, Najarian JS: Beneficial effects of establishing pancreatic duct drainage into a hollow organ (bladder, jejunum, or stomach) compared to free intraperitoneal drainage or duct injection. *Transplant Proc* 17: 366–371, 1985
80. Munda R, Berlatzky Y, Jonung M, Murphy RF, Brackett K, Joffe SN, Alexander JW: Studies on segmental pancreatic autotransplants in dogs. *Arch Surg* 118: 1310–1315, 1983
81. Scharp DW, Downing R, Merrell RC, Greider M: Isolating the elusive islet. *Diabetes* 29 (Suppl 1): 19–30, 1980
82. Hellerström C: A method for the microdissection of intact pancreatic islets of mammals. *Acta Endocrinol* 45: 122–132, 1964
83. Moskalewski S: Isolation and culture of the islets of Langerhans of the guinea pig. *Gen Comp Endocrinol* 5: 342–353, 1965
84. Lacy PE, Kostianovsky M: Method for the isolation of intact islets of Langerhans from the rat pancreas. *Diabetes* 16: 35–39, 1967
85. Younoszai R, Sorenson RL, Lindall AW: Homotransplantation of isologous pancreatic islets. *Diabetes* 19: 406, 1970
86. Ballinger WF, Lacy PE: Transplantation of intact pancreatic islets in rats. *Surgery* 72: 175–186, 1972
87. Fritschy WM, Van Straaten JFM, de Vos P, Strubbe JH, Wolters GHJ, Van Schilfgaarde R: The efficacy of intraperitoneal pancreatic islet isografts in the reversal of diabetes in rats. *Transplantation* 52: 777–783, 1991
88. Winoto-Morbach S, Ulrichs K, Hering BJ, Leyhausen G, Müller-Ruchholz W: Lectins for electromagnetic purification of islets from humans and large mammals lectin. In *Methods in islet transplantation research: international workshop, Bad Neuheim, June 1989*. Federlin K,

- Bretzel RG, Hering BJ, Hetzel WD, Hoffmann AR, Pfeiffer EF, Reaven GM, Eds. New York, Thieme Medical Publ., 1990, p. 51–54
89. Gray DWR, McShane P, Morris PJ: The effect of hyperglycemia on isolated rodent islets transplanted to the kidney capsule site. *Transplantation* 41: 699–703, 1986
 90. Mirkovitch V: Successful intrasplenic autotransplantation of pancreatic tissue in totally pancreatectomised dogs. *Transplantation* 21: 265–269, 1976
 91. Kretschmer GJ, Sutherland DER, Matas AJ, Cain TL, Najarian JS: Autotransplantation of pancreatic islets without separation of exocrine and endocrine tissue in totally pancreatectomized dogs. *Surgery* 82: 74–81, 1977
 92. Warnock GL, Ao Z, Cattral MS, Dabbs KD, Rajotte RV: Experimental islet transplantation in large animals. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 261–78
 93. Largiader F, Kolb E, Biswanger U: A long-term functioning human pancreatic islet allotransplant. *Transplantation* 29: 76–77, 1980
 94. London NJM, James RFL, Bell PRF: Islet purification. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 113–123
 95. Horaguchi A, Merrell RC: Preparation of viable islet cells from dogs by a new method. *Diabetes* 30: 455–458, 1981
 96. Noel J, Rabinovitch A, Olson L, Kyriakides G, Miller J, Mintz DH: A method for large-scale, high-yield isolation of canine pancreatic islets of Langerhans. *Metabolism* 31: 184–187, 1982
 97. Long JA, Britt LD, Olack BJ, Scharp DW: Autotransplantation of isolated canine pancreatic islet cells. *Transplant Proc* 15: 1332–1337, 1983
 98. Warnock GL, Rajotte RV, Procyshyn AW: Normoglycemia after reflux of islet-containing pancreatic fragments into the splenic vascular bed in dogs. *Diabetes* 32: 452–459, 1983
 99. Hesse U, Sutherland DER, Florack G, Field J, Ward S, Najarian JS: Comparison of two methods of islet preparation and transplantation in dogs. *Diabetes* 35: 1109–1118, 1986
 100. Gray DWR, McShane P, Grant A, Morris PJ: A method for isolation of islets of Langerhans from the human pancreas. *Diabetes* 33: 1055–1061, 1984
 101. Ricordi C, Gray DWR, Hering BJ, Kaufman DB, Warnock GL, Kneteman NM, Lake SP, London NJM, Socci C, Alejandro R, Zeng Y, Scharp DW, Viviani G, Falqui L, Tzakis A, Bretzel RG, Federlin K, Pozza G, James RFL, Rajotte RV, Di Carlo V, Morris PJ, Sutherland DER, Starzl TE, Mintz DH, Lacy PE: Islet isolation assessment in man and large animals. *Acta diabetol lat* 27: 185–195, 1990
 102. Van der Burg MPM, Gooszen HG, Terpstra JL, Frölich M, Scherft JP, Lemkes HHPJ: Quantification of canine pancreatic islet isolation (Abstract). *Diabetes* 38 (Suppl 1): 274, 1989
 103. Alderson D, Kneteman NM, Olack BJ, Scharp DW: Isolation and quantification of canine islet tissue for transplantation. *Transplantation* 43: 579–581, 1987
 104. Warnock GL, Rajotte RV: Critical mass of purified islets that induce normoglycemia after implantation into dogs. *Diabetes* 37: 467–470, 1988
 105. Van der Burg MPM, Gooszen HG, Field MJ, Scherft JP, Terpstra JL, Van de Woude FJ, Guicherit OR, Frölich M, Bruijn JA: Comparison of current islet isolation techniques in dogs. *Transplant Proc* 22: 2044–2045, 1990
 106. Gray DWR, Leow CK: Non-automated methods for islet isolation. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 89–98
 107. Wolters GHJ, Van Suylichem PTR, Van Deijnen JHM, Van Schilfgaarde R: Factors influencing the isolation process of islets of Langerhans. In *Methods in islet transplantation research: international workshop, Bad Neuheim, June 1989*. Federlin K, Bretzel RG, Hering BJ,

- Hetzel WD, Hoffmann AR, Pfeiffer EF, Reaven GM, Eds. New York, Thieme Medical Publ., 1990, p. 20–26
108. Van der Burg MPM, Gooszen HG, Ploeg RJ, Scherft JP, Field MJ, Guicherit OR, Terpstra JL, Van de Woude FJ, Frölich M, Bruijn JA: Comparison of islet isolation techniques in dogs: Over 90% purified islets using UW solution. *Transplant Proc* 22: 795–796, 1990
 109. Van der Burg MPM, Gooszen HG, Ploeg RJ, Guicherit OR, Scherft JP, Terpstra JL, Bruijn JA, Frölich M: Pancreatic islet isolation with UW solution: a new concept. *Transplant Proc* 22: 2050–2051, 1990
 110. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW: Automated method for isolation of human pancreatic islets. *Diabetes* 37: 413–420, 1988
 111. Shibata A, Ludvigsen CW, Naber SP, McDaniel ML, Lacy PE: Standardization of a digestion-filtration method for isolation of pancreatic islets. *Diabetes* 25: 667–672, 1976
 112. Alejandro R, Cutfield RG, Shienvold FL, Polonsky KS, Noel J, Olson L, Dillberger J, Miller J, Mintz DH: Natural history of intrahepatic canine islet cell autografts. *J Clin Invest* 78: 1339–1348, 1986
 113. Kaufman DB, Morel Ph, Field MJ, Munn SR, Sutherland DER: Purified canine islet autografts: functional outcome as influenced by islet number and implantation site. *Transplantation* 50: 385–391, 1990
 114. Sutton R, Gray DER, Burnett M, McShane Ph, Turner RC, Morris PJ: Metabolic function of intraportal and intrasplenic islet autografts in cynomolgus monkeys. *Diabetes* 38 (Suppl 1): 182–184, 1989
 115. Van der Burg MPM, Guicherit OR, Scherft JP, Lemkes HHPJ, Frölich M, Gooszen HG: Metabolic control after canine islet transplantation (Abstract). *Diabetologia* 33 (Suppl): A178, 1990
 116. Van der Burg MPM, Guicherit OR, Ploeg RJ, Frölich M, Bruijn JA, Scherft JP, Gooszen HG: Metabolic control after autotransplantation of highly purified canine pancreatic islets isolated in UW-solution. *Transplant Proc* 23: 785–786, 1991
 117. Islet Transplant Registry. Hering BJ, Browatzki CC, Schultz AO, Watz B, Bretzel RG, Federlin K Eds. *ITR Newsletter* No. 5 Vol.4 (No.1), Giessen, Germany, 1994
 118. Bretzel RG, Alejandro R, Hering BJ, Van Suylichem PTR, Ricordi C: Clinical islet transplantation: guidelines for islet quality control. *Transplant Proc* 26: 388–392, 1994
 119. Alejandro R, Mintz DH: Effect of cyclosporine and FK506 on insulin secretion in normal dogs and dogs with intraportal islet cell autografts. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 352–360
 120. Van Schilfgaarde R, Van der Burg MPM, Van Suylichem PTR, Frölich M, Gooszen HG, Moolenaar AJ: Interference by cyclosporine with the endocrine function of the canine pancreas. *Transplantation* 44: 13–16, 1987
 121. Scharp DW, Alderson D, Kneteman NM: Optimization of islet preparations for clinical transplantation. *Transplant Proc* 18: 1814–1816, 1986
 122. Wahlberg J, Jacobsson J, Tufveson G: Relevance of additive components of University of Wisconsin cold-storage solution. *Transplantation* 48: 400–403, 1989
 123. Southard JH, Van Gulik TM, Ametani MS, Vreugdenhil PK, Lindell SL, Pienaar BL, Belzer FO: Important components of the UW solution. *Transplantation* 49: 251–257, 1990
 124. Wahlberg JA, Love R, Landegaard L, Southard JH, Belzer FO: 72-hour preservation of the canine pancreas. *Transplantation* 43: 5–8, 1987
 125. Van der Burg MPM, Gooszen HG: The metabolic efficiency of islet grafts: an overview. In *Islet transplantation — current status of clinical application and experimental results..* Hesse UJ, Pichlmaier H, Eds. Lengerich, Germany, Wolfgang Pabst Verlag, 1992, p. 93–99
 126. Hellerström C: The life story of the pancreatic B cell. *Diabetologia* 26: 393–400, 1984

127. Weir GC, Bonner-Weir S: Islets of Langerhans: the puzzle of intraislet interactions and their relevance to diabetes. *J Clin Invest* 85: 983–987, 1990
128. Stagner JI: Pulsatile secretion from the endocrine pancreas: metabolic, hormonal, and neural modulation. In *The endocrine pancreas*. Samols E, Ed. New York, Raven Press, 1991, p. 283–302
129. Strubbe JH, Steffens AB: Neural control of insulin secretion. *Horm metab Res* 25: 507–512, 1993
130. Dupre J: Influences of the gut on the endocrine pancreas: an overview of established and potential physiological mechanisms. In *The endocrine pancreas*. Samols E, Ed. New York, Raven Press, 1991, p. 253–281
131. Ebert R: Gut signals for islet hormone release. *Eur J Clin Invest* 20 (Suppl 1): S20–S26, 1990
132. Trimble ER: Pancreatic islet—acinar relationships. In *Pancreatic islet cell transplantation*. Ricordi C, Ed. Austin, Landes Company, 1992, p. 19–25

